


FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.

Client Ref.

056291-5039



**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: PEARS et al.

Appln. No.: 09/889,414

Filing Date: November 13, 2001

Date: March 10, 2004

Page 1 of 1

Examiner: Meller, Michael V. Group Art Unit: 1654

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						
FR						

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
						Enclosed	No
GR							
HR							
IR							
JR							
KR							
LR							
MR							
NR							
OR							
PR							

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

MVM	QR	Hunninghake, "HMG CoA reductase inhibitors", Current Opinion in Lipidology 1992; 3:22-28 (cited in the specification at page 3, lines 11-12).
MVM	RR	Miller et al., "Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)", Clin Pharmacokinet 1998 Feb; 34(2): 155-162.
MVM	SR	Williams et al., "Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors", Clin Pharmacokinet 2002; 41(5): 343-370.
	TR	
	UR	
	VR	
	WR	
	XR	

Examiner

Date Considered:

5/10/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.